LU92327I9 - - Google Patents

Info

Publication number
LU92327I9
LU92327I9 LU92327C LU92327C LU92327I9 LU 92327 I9 LU92327 I9 LU 92327I9 LU 92327 C LU92327 C LU 92327C LU 92327 C LU92327 C LU 92327C LU 92327 I9 LU92327 I9 LU 92327I9
Authority
LU
Luxembourg
Application number
LU92327C
Other versions
LU92327I2 (fr
Inventor
Tomi K Sawyer
Chester A Metcalf Iii
Dong ZOU
Wei-Sheng Huang
William C Shakespeare
Yihan Wang
R Mathew Thomas
Jan Antoinette C Romero
Jiwei Qi
Xiaotian Zhu
Rajeswari Sundaramoorthi
David C Dalgarno
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92327(I9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Publication of LU92327I2 publication Critical patent/LU92327I2/fr
Publication of LU92327I9 publication Critical patent/LU92327I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LU92327C 2005-12-23 2013-12-05 Ponatinib sous toutes ses formes telles que protégées par le brevet de base LU92327I2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US75400005P 2005-12-23 2005-12-23
US75396205P 2005-12-23 2005-12-23
US75608906P 2006-01-03 2006-01-03
US79847206P 2006-05-08 2006-05-08
US83319106P 2006-07-25 2006-07-25
PCT/US2006/048758 WO2007075869A2 (fr) 2005-12-23 2006-12-22 Composes heteroaryles bicycliques

Publications (2)

Publication Number Publication Date
LU92327I2 LU92327I2 (fr) 2014-02-05
LU92327I9 true LU92327I9 (fr) 2019-01-16

Family

ID=38218600

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92327C LU92327I2 (fr) 2005-12-23 2013-12-05 Ponatinib sous toutes ses formes telles que protégées par le brevet de base

Country Status (20)

Country Link
US (9) US8114874B2 (fr)
EP (4) EP1973545B1 (fr)
JP (3) JP5200939B2 (fr)
KR (1) KR101436303B1 (fr)
CN (1) CN103044432B (fr)
AU (1) AU2006331673B2 (fr)
CA (1) CA2634923C (fr)
CY (3) CY1113907T1 (fr)
DK (2) DK2495016T3 (fr)
EA (2) EA027573B1 (fr)
ES (2) ES2403206T3 (fr)
HU (2) HUE047422T2 (fr)
IL (2) IL191938A (fr)
LT (1) LT2495016T (fr)
LU (1) LU92327I2 (fr)
MX (2) MX2008008152A (fr)
PL (2) PL1973545T3 (fr)
PT (2) PT2495016T (fr)
SI (1) SI2495016T1 (fr)
WO (1) WO2007075869A2 (fr)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071609B2 (en) 2005-08-11 2011-12-06 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
WO2007075869A2 (fr) * 2005-12-23 2007-07-05 Ariad Pharmaceuticals, Inc. Composes heteroaryles bicycliques
MX2008014290A (es) * 2006-05-08 2008-11-26 Ariad Pharma Inc Compuestos heteroarilicos monociclicos.
CN103435595A (zh) 2006-05-08 2013-12-11 阿里亚德医药股份有限公司 炔类杂芳基化合物
CA2660836A1 (fr) 2006-08-07 2008-02-21 Incyte Corporation Utilisation de triazolotriazines en tant qu'inhibiteurs des kinases
US8143410B2 (en) 2006-11-16 2012-03-27 Allergan, Inc. Kinase inhibitors
US8558002B2 (en) 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
CA2669704A1 (fr) 2006-11-16 2008-05-22 Allergan, Inc. Sulfoximines en tant qu'inhibiteurs de la kinase
EA026126B1 (ru) 2006-11-22 2017-03-31 Инсайт Холдингс Корпорейшн Имидазотриазины и имидазопиримидины в качестве ингибиторов киназы
EP2070929A1 (fr) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Composés d'alkynylaryle et sels correspondants, compositions pharmaceutiques contenant ceux-ci, procédés de préparation de ceux-ci et usage de ceux-ci
WO2009143211A2 (fr) 2008-05-21 2009-11-26 Incyte Corporation Sels de 2-fluoro-n-méthyl-4-[7-(quinoléin-6-yl-méthyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide et procédés associés à leur préparation
FR2933981A1 (fr) * 2008-07-18 2010-01-22 Sanofi Aventis NOUVEAUX DERIVES IMIDAZO°1,2-a!PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
US8455477B2 (en) * 2008-08-05 2013-06-04 Merck Sharp & Dohme Corp. Therapeutic compounds
CA2743449C (fr) 2008-11-12 2016-10-18 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines et derives utiles comme inhibiteurs de kinases
JP2013509444A (ja) * 2009-10-30 2013-03-14 アリアド・ファーマシューティカルズ・インコーポレイテッド がんの治療方法及び治療用組成物
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
BR112012019302B1 (pt) 2010-02-03 2022-06-21 Incyte Holdings Corporation Imidazo[1,2-b] [1,2,4]triazinas como inibidores de c-met, composição que as compreende e métodos in vitro de inibir a atividade de c-met cinase, de inibir a via de sinalização da hgf/c-met cinase em uma célula e de inibir a atividade proliferativa de uma célula
CN101885722B (zh) * 2010-07-01 2013-07-24 中国科学院广州生物医药与健康研究院 杂环炔苯类化合物及其药用组合物和应用
US8846671B2 (en) 2010-07-01 2014-09-30 Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
US9024021B2 (en) 2011-01-21 2015-05-05 Sun Pharma Advanced Research Company Ltd. Diarylacetylene hydrazide containing tyrosine kinase inhibitors
WO2012127030A1 (fr) * 2011-03-23 2012-09-27 Proteosys Ag Arylpipérazines en tant qu'agents neuroprotecteurs
KR20140022062A (ko) * 2011-04-07 2014-02-21 어리어드 파마슈티칼스, 인코포레이티드 파킨슨병을 치료하기 위한 방법 및 조성물
WO2012139027A1 (fr) * 2011-04-07 2012-10-11 Ariad Pharmaceuticals, Inc. Procédés et compositions pour le traitement de maladies neurodégénératives
RU2477723C2 (ru) * 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
AU2012340200B2 (en) 2011-11-17 2017-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-Terminal Kinase (JNK)
WO2013162727A1 (fr) * 2012-04-25 2013-10-31 Ariad Pharmaceuticals, Inc. Procédés et compositions pour le traitement de maladies médiées par la kinase raf
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
WO2013170770A1 (fr) * 2012-05-16 2013-11-21 上海医药集团股份有限公司 Dérivés d'acétylène ayant une activité antitumorale
US8859553B2 (en) * 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
WO2014028595A1 (fr) * 2012-08-14 2014-02-20 Concert Pharmaceuticals, Inc. Ponatinib deutéré
CN103664787B (zh) * 2012-09-17 2015-09-09 南京圣和药业股份有限公司 炔杂芳环化合物及其应用
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063061A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
TWI574962B (zh) * 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
CN103848829B (zh) 2012-11-28 2017-04-12 南京圣和药业股份有限公司 杂芳基炔烃化合物及其应用
CA3022250A1 (fr) * 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Formes cristallines de 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperaz in-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
US20140343282A1 (en) 2013-05-16 2014-11-20 Apicore, Llc Processes for making ponatinib and intermediates thereof
US9725454B2 (en) 2013-07-04 2017-08-08 Sandoz Ag Crystalline forms of ponatinib hydrochloride
CN104341416B (zh) * 2013-07-31 2017-03-29 南京圣和药业股份有限公司 蛋白酪氨酸激酶抑制剂及其应用
GB2518873A (en) * 2013-10-03 2015-04-08 Agency Science Tech & Res Bicyclic alkyne derivatives and uses thereof
CA2927917C (fr) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Composes heteroaromatiques utiles pour le traitement des maladies proliferatives
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN104650086A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 盐酸帕纳替尼化合物
WO2015085971A1 (fr) 2013-12-09 2015-06-18 Zentiva, K.S. Sel bromhydrate de 3-(2-imidazo[1,2-b]pyridazin-3-yl-éthynyl)-4-méthyl-n-[4-[(4-méthyl-1-pipérazinyl)méthyl]-3-(trifluorométhyl)phényl]benzamide
WO2015085972A1 (fr) 2013-12-09 2015-06-18 Zentiva, K.S. Nouveaux sels de 3-(2-imidazo[1,2-b]pyridazin-3-yl-éthynyl)-4-méthyl-n-[4-[(4-méthyl-1-pipérazinyl)méthyl]-3-(trifluorométhyl)phényl]benzamide
WO2015085973A1 (fr) 2013-12-09 2015-06-18 Zentiva, K.S. Modifications de sel de chlorhydrate de 3-(2-imidazo[1,2-b]pyridazine-3-yléthynyl)-4-méthyl-n-[4-[(4-méthyl-1-pipérazinyl)méthyl]-3-(trifluorométhyl)phényl] benzamide
CN104496995A (zh) * 2014-01-06 2015-04-08 广东东阳光药业有限公司 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法
GB2522226A (en) * 2014-01-17 2015-07-22 Agency Science Tech & Res Heteroaryl alkyne derivatives and uses thereof
WO2015164604A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées
WO2015164614A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase et leurs utilisations
BR112016028674A2 (pt) 2014-06-06 2017-08-22 Natco Pharma Ltd ?1h-1, 8-naftiridin-2-onas como compostos antiproliferativos?
CA2952083C (fr) 2014-07-17 2023-01-24 Sunshine Lake Pharma Co., Ltd. Derives d'uree substitues et utilisations pharmaceutiques de ceux-ci
WO2016059220A1 (fr) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Agents d'activation du tcr à utiliser dans le traitement de la lla-t
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
CN105837575B (zh) * 2015-01-13 2019-01-15 四川大学 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
EP3273966B1 (fr) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
CN106167491A (zh) * 2015-05-19 2016-11-30 重庆大学 一种有效抑制肺癌转移的化合物及其应用
WO2016201203A1 (fr) * 2015-06-11 2016-12-15 Apicore Us Llc Procédés de fabrication de ponatinib et de ses intermédiaires
EP3307728A4 (fr) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
WO2017044623A1 (fr) * 2015-09-09 2017-03-16 Lau Warren C Méthodes, compositions et utilisations de nouveaux inhibiteurs de la kinase fyn
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
WO2017152126A1 (fr) 2016-03-03 2017-09-08 Cornell University Inhibiteurs ire1-alpha à petites molécules
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2017222287A1 (fr) * 2016-06-20 2017-12-28 재단법인 대구경북첨단의료산업진흥재단 Nouveau dérivé d'imidazopyridine, son procédé de préparation, et composition pharmaceutique contenant celui-ci comme principe actif pour la prévention ou le traitement du cancer
WO2018002958A1 (fr) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Nouveaux composés contenant de l'hydrazide utilisés comme inhibiteurs de btk
US10221184B2 (en) 2017-01-20 2019-03-05 Apicore Us Llc Polymorphs of ponatinib hydrochloride
MA47793A (fr) * 2017-03-15 2020-01-22 Sun Pharma Advanced Res Co Ltd Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque
CA3056356A1 (fr) 2017-03-15 2018-09-20 Sun Pharma Advanced Research Company Limited Nouvelle dispersion amorphe d'acide cyclopropanecarboxylique (5-{5-[ n'-(2-chloro-6-methylbenzoyl) hydrazinocarbonyl] -2-methyl-phenylethynyl}-pyridin-2-yl) amide
US11072620B2 (en) 2017-06-20 2021-07-27 Apotex Inc. Crystalline forms of Ponatinib hydrochloride
JP7024960B2 (ja) * 2017-10-04 2022-02-24 国立大学法人京都大学 Ｂｃｒ－Ａｂｌタンパク質イメージング用分子プローブ
WO2019246479A1 (fr) 2018-06-22 2019-12-26 Johnson Matthey Public Limited Company Forme de ponatinib
US11840535B2 (en) 2018-07-02 2023-12-12 Shenzhen Targetrx, Inc. Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity
EP3808746B1 (fr) * 2018-07-17 2023-08-02 Shenzhen TargetRx, Inc. Dérivés de n-[3-[2-[8-[(1h-pyrazol-4-yl)amino]imidazo[1,2-a]pyrazin-3-yl]éthynyl]phényl]-benzamide et composés similaires en tant qu'inhibiteurs de protéine kinase pour le traitement du cancer
JP7474752B2 (ja) * 2018-09-12 2024-04-25 パデュー リサーチ ファウンデイション キナーゼ阻害剤としてのアルキニルニコチンアミド化合物
US11427591B2 (en) 2018-10-17 2022-08-30 Insilico Medicine Ip Limited Kinase inhibitors
JP2022515705A (ja) 2018-11-01 2022-02-22 サイロス ファーマシューティカルズ， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の非共有結合性阻害剤を用いてバイオマーカーにより特定された患者におけるがんを処置する方法
WO2020130125A1 (fr) 2018-12-21 2020-06-25 第一三共株式会社 Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de kinase
WO2020214999A1 (fr) * 2019-04-17 2020-10-22 Emory University Composés tyrosine kinase non récepteur abelson pour le traitement de maladies neurodégénératives
WO2020223235A1 (fr) 2019-04-29 2020-11-05 Incyte Corporation Formes pharmaceutiques de ponatinib du type mini-comprimés
KR102205619B1 (ko) 2019-06-12 2021-01-21 한국과학기술연구원 신규한 인다졸 유도체 화합물 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN111004240B (zh) * 2019-12-13 2020-12-01 山东铂源药业有限公司 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法
EP4146639A1 (fr) 2020-05-06 2023-03-15 Ajax Therapeutics, Inc. 6-hétéroaryloxy benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2
WO2021228983A1 (fr) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Composition pharmaceutique comprenant un composé à base d'arsenic, un inducteur d'ifn de type 1 et un inhibiteur de protéine kinase permettant de traiter le cancer
US20230219934A1 (en) * 2020-06-24 2023-07-13 Purdue Research Foundation 2,3-disubstituted pyrido[3,4-b]pyrazine-containing compounds as kinase inhibitors
WO2022053130A1 (fr) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 pour le traitement des cancers induits par v-src, c-src-tyrosine kinase
EP4267574A1 (fr) 2020-12-23 2023-11-01 Ajax Therapeutics, Inc. 6-hétéroaryloxy benzimidazoles et azabenzimidazoles utilisés en tant qu'inhibiteurs de jak2
US20220289756A1 (en) * 2021-03-11 2022-09-15 Wai Kit Pang Compounds and compositions as inhibitors of protein kinases
CN112778207A (zh) * 2021-03-19 2021-05-11 海南鑫开源医药科技有限公司 一种盐酸尼洛替尼原料药杂质及其制备方法
AU2021440841A1 (en) * 2021-04-13 2023-10-19 Shenzhen Newdel Biotech Co., Ltd. Alkynylphenylbenzamide compound and use thereof
US20240199626A1 (en) * 2021-04-19 2024-06-20 Oregon Health & Science University Compounds with improved cardiac safety for the treatment of cancer and neurodegenerative disorders
AU2022379973A1 (en) 2021-11-08 2024-06-27 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
TW202334139A (zh) 2021-11-09 2023-09-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳氧基苯并咪唑及氮雜苯并咪唑
WO2024149365A1 (fr) * 2023-01-13 2024-07-18 Shenzhen Newdel Biotech Co., Ltd. Sels et formes cristallines du composé a, procédés de préparation et utilisations de ceux-ci

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5099057A (en) 1987-10-19 1992-03-24 The Dow Chemical Company Process for the preparation of ar-amino-para-arenediols
US5099067A (en) 1988-08-05 1992-03-24 Northwestern University Use of ammonium formate as a hydrogen transfer reagent for reduction of chiral nitro compounds with retention of configuration
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
ATE117690T1 (de) 1990-03-01 1995-02-15 Takeda Chemical Industries Ltd Imidazopyridazine, ihre herstellung und verwendung.
KR19990008451A (ko) 1995-05-09 1999-01-25 페라스타르크 피라졸로-(1,5ａ)-피리미딘, 그의 제조 방법 및 용도
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
ES2240202T3 (es) 1999-11-08 2005-10-16 Schering Corporation Procedimiento de preparacion de n-(4-hidroxifenil)-n'-(4'-aminofenil)piperazina.
US6420365B1 (en) 2000-01-18 2002-07-16 Neurogen Corporation Imidazopyridines and related derivatives as selective modulators of bradykinin B2 receptors
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE10019714A1 (de) 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
CA2419626A1 (fr) 2000-07-14 2002-01-24 Rajagopal Bakthavatachalam Imidazo¬1,2-a|pyrazines destinees au traitement d'affections neurologiques
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE10117184A1 (de) 2001-04-05 2002-10-17 Gruenenthal Gmbh Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen
DE10117183A1 (de) 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
PT1399468E (pt) 2001-05-30 2006-05-31 Novartis Ag Derivados do acido 2-{[n-(2-amino-3-(heteroaril ou aril)propionil)-aminoacil]-amino}-alquilboronico
EP1408980A4 (fr) 2001-06-21 2004-10-20 Ariad Pharma Inc Nouvelles quinazolines et leur utilisation
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
EP1431299B1 (fr) 2001-09-04 2007-05-23 Sumitomo Chemical Company, Limited IMIDAZO(1,2-a)PYRIMIDINES ET COMPOSITIONS FONGICIDES LES CONTENANT
KR100956195B1 (ko) 2002-02-01 2010-05-06 어리어드 파마슈티칼스, 인코포레이티드 인 함유 화합물 및 이의 용도
BR0309398A (pt) 2002-04-19 2005-02-01 Cellular Genomics Inc Composto ou um seu sal, hidrato, solvato, forma cristalina, diastereÈmero, prodroga farmaceuticamente aceitável, ou misturas deles, composição farmacêutica, e, métodos para tratar uma condição envolvida com a cinase em um mamìfero, para tratar câncer, e para identificar uma cinase
CA2487900A1 (fr) * 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Inhibiteurs de proteines-kinases en relation a l'immunite
EP1541575B1 (fr) 2002-07-29 2010-03-03 Sumitomo Chemical Company, Limited Nouveau procede pour produire un derive d'imidazo(1,2-b)pyridazine
CA2466772C (fr) 2002-09-11 2012-08-28 Becton, Dickinson And Company Appareil et methode permettant de surveiller la glycemie, comprenant notamment un affichage convivial de la moyenne des valeurs de glycemie et des valeurs constituantes
DE10246890A1 (de) 2002-10-08 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-alpyridin-3-yl-methylamine
DE10247269A1 (de) 2002-10-10 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine
AR041992A1 (es) * 2002-11-06 2005-06-08 Smithkline Beecham Corp Compuesto de piridinil benzoheterociclico, composicion farmaceutica que lo comprende y su uso para prepararla
GB0230089D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
EP1615697A2 (fr) 2003-04-11 2006-01-18 Novo Nordisk A/S Utilisation pharmaceutique de pyrazolo 1,5-a]pyrimidines substituees
PL1684763T3 (pl) 2003-09-24 2008-11-28 Wyeth Corp 6-arylo-7-halogeno-imidazo[1,2-a]pirymidyny jako środki przeciwnowotworowe
WO2005047290A2 (fr) 2003-11-11 2005-05-26 Cellular Genomics Inc. Certaines imidazo[1,2-a]pyrazin-8-ylamines, procede de fabrication et methode d'utilisation
AU2004292773A1 (en) 2003-11-28 2005-06-09 Novartis Ag Diaryl urea derivatives in the treatment of protein kinase dependent diseases
KR20060125830A (ko) 2003-12-05 2006-12-06 캠브리지 바이오테크놀로지 리미티드 2―치환 아데노신의 개선된 합성
ATE415970T1 (de) 2003-12-24 2008-12-15 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
JP2007517006A (ja) * 2003-12-24 2007-06-28 アストラゼネカ アクチボラグ Ｔｉｅ２（ｔｅｋ）活性のあるピリミジン
AR049769A1 (es) 2004-01-22 2006-09-06 Novartis Ag Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
MXPA06011678A (es) * 2004-04-07 2007-01-23 Applied Research Systems Derivados de 1,1??(1,2-etinediil)bis-benceno como inhibidores de proteina-tirosina fosfatasa 1-b.
DE102004021716A1 (de) 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
AU2005275181A1 (en) * 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
KR100973609B1 (ko) * 2005-03-23 2010-08-03 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ2 길항제로서 아세틸렌일-피라졸로-피리미딘유도체
JP2008534565A (ja) 2005-03-31 2008-08-28 アストラゼネカ アクチボラグ Ｔｉｅ２阻害活性のあるアミノピリミジン誘導体
WO2007013673A1 (fr) 2005-07-29 2007-02-01 Astellas Pharma Inc. Hétérocycles fusionnés en tant qu’inhibiteurs de lck
US8071609B2 (en) 2005-08-11 2011-12-06 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
SI1973545T1 (sl) * 2005-12-23 2013-04-30 Ariad Pharmaceuticals, Inc. Spojine bicikličnega heteroarila
WO2007075869A2 (fr) 2005-12-23 2007-07-05 Ariad Pharmaceuticals, Inc. Composes heteroaryles bicycliques
CN103435595A (zh) * 2006-05-08 2013-12-11 阿里亚德医药股份有限公司 炔类杂芳基化合物
MX2008014290A (es) * 2006-05-08 2008-11-26 Ariad Pharma Inc Compuestos heteroarilicos monociclicos.
EP2107054A1 (fr) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Composés antiprolifératives et ses utilisations thérapeutiques
WO2010124047A1 (fr) 2009-04-23 2010-10-28 Wyeth Llc Bisaryl alcynylamides en tant que modulateurs allostériques négatifs du récepteur métabotropique du glutamate 5 (mglur5)
US8461851B2 (en) 2009-06-08 2013-06-11 University Of Hawaii Systems for transverse electromagnetic mode in-situ soil testing
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP2013509444A (ja) 2009-10-30 2013-03-14 アリアド・ファーマシューティカルズ・インコーポレイテッド がんの治療方法及び治療用組成物
WO2012139027A1 (fr) 2011-04-07 2012-10-11 Ariad Pharmaceuticals, Inc. Procédés et compositions pour le traitement de maladies neurodégénératives
JP5300939B2 (ja) * 2011-08-25 2013-09-25 安田工業株式会社 仕上加工用工具を用いた加工方法
CA3022250A1 (fr) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Formes cristallines de 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperaz in-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Also Published As

Publication number Publication date
CY2013044I2 (el) 2015-11-04
AU2006331673A1 (en) 2007-07-05
US8778942B2 (en) 2014-07-15
BRPI0621098A2 (pt) 2013-04-02
AU2006331673B2 (en) 2013-02-28
US20220081440A1 (en) 2022-03-17
JP5200939B2 (ja) 2013-06-05
SI2495016T1 (sl) 2020-04-30
CY1113907T1 (el) 2015-11-04
US20140288082A1 (en) 2014-09-25
US20120135986A1 (en) 2012-05-31
IL191938A (en) 2016-03-31
EA200870116A1 (ru) 2009-10-30
IL239445A (en) 2017-02-28
HUE047422T2 (hu) 2020-04-28
EA034598B1 (ru) 2020-02-25
CY2013044I1 (el) 2015-11-04
JP2013064004A (ja) 2013-04-11
DK1973545T3 (da) 2013-02-25
EA027573B1 (ru) 2017-08-31
US20190031656A1 (en) 2019-01-31
EP1973545A4 (fr) 2010-03-10
EP1973545A2 (fr) 2008-10-01
PL1973545T3 (pl) 2013-05-31
JP2015147796A (ja) 2015-08-20
US20130196979A1 (en) 2013-08-01
EP2495016A1 (fr) 2012-09-05
EP1973545B1 (fr) 2013-01-30
US20160368917A1 (en) 2016-12-22
CA2634923C (fr) 2015-05-05
EP3417912A1 (fr) 2018-12-26
PL2495016T3 (pl) 2020-06-01
US9278971B2 (en) 2016-03-08
ES2761180T3 (es) 2020-05-19
CN103044432B (zh) 2016-08-03
PT1973545E (pt) 2013-02-11
WO2007075869A2 (fr) 2007-07-05
LT2495016T (lt) 2020-02-10
EP3417912B1 (fr) 2020-08-12
MX2008008152A (es) 2008-09-12
WO2007075869A3 (fr) 2007-11-29
CY1122646T1 (el) 2020-10-14
DK2495016T3 (da) 2019-12-16
ES2403206T3 (es) 2013-05-16
US9029533B2 (en) 2015-05-12
CA2634923A1 (fr) 2007-07-05
CN103044432A (zh) 2013-04-17
US20200231588A1 (en) 2020-07-23
EP3747441A1 (fr) 2020-12-09
JP5790629B2 (ja) 2015-10-07
US20130231337A1 (en) 2013-09-05
US8470851B2 (en) 2013-06-25
US20070191376A1 (en) 2007-08-16
JP2009521462A (ja) 2009-06-04
EA201790678A1 (ru) 2017-12-29
JP6604739B2 (ja) 2019-11-13
EP2495016B1 (fr) 2019-10-16
IL191938A0 (en) 2009-08-03
HUS1300078I1 (hu) 2018-11-28
MX343042B (es) 2016-10-21
LU92327I2 (fr) 2014-02-05
IL239445A0 (en) 2015-07-30
KR20080081191A (ko) 2008-09-08
US8114874B2 (en) 2012-02-14
PT2495016T (pt) 2019-12-16
KR101436303B1 (ko) 2014-09-02

Similar Documents

Publication Publication Date Title
BE2012C042I2 (fr)
BRPI0601358B8 (pt) Aplicador de clipe cirúrgico
BRPI0601402B8 (pt) Aplicador de grampos cirúrgicos
BR122017004707A2 (fr)
BRPI0609157A8 (fr)
BRPI0608519A2 (fr)
BR122020005056A2 (fr)
AP2140A (fr)
BR122016029989A2 (fr)
BRPI0604219A (fr)
ECSMU066687U (fr)
BRPI0618215B8 (fr)
BY2237U (fr)
CN105122969C (fr)
CN300725994S (zh) 鞋底
CN300726002S (zh) 鞋帮
CN300726699S (zh) 调料瓶套装(d)
CN300726698S (zh) 调料瓶套装(e)
CN300770152S (zh) 玩具车
CN300725990S (zh) 鞋帮
CN300725991S (zh) 鞋帮
CN300725992S (zh) 鞋底
CN300725993S (zh) 鞋帮
CN300743872S (zh) 锡工剪
CN300725995S (zh) 鞋帮